Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 20/20 | 1.00 |
| ▸ | HSP90B1 | P14625 | 2/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.75 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.75 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.75 |
| ▸ | CDC37 | Q16543 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18431832 | 0.95 | HSP90AA1 (0.90) | HSP90AA1HSP90B1ERBB2HSP90AB1TRAP1 | |
| SCHEMBL1743323 | 0.95 | HSP90AA1 (1.00) | HSP90AA1HSP90B1CDC37 | |
| SCHEMBL4139422 | 0.92 | HSP90AA1 (1.00) | HSP90AA1HSP90B1CDC37 | |
| SCHEMBL15980439 | 0.91 | HSP90AA1 (0.83) | HSP90AA1HSP90B1ERBB2HSP90AB1TRAP1 | |
| SCHEMBL15980522 | 0.90 | HSP90AA1 (0.81) | HSP90AA1HSP90B1ERBB2HSP90AB1TRAP1 | |
| SCHEMBL15980541 | 0.90 | HSP90AA1 (0.81) | HSP90AA1HSP90B1ERBB2HSP90AB1TRAP1 | |
| SCHEMBL17449251 | 0.90 | HSP90AA1 (0.81) | HSP90AA1HSP90B1ERBB2HSP90AB1TRAP1 | |
| SCHEMBL4135031 | 0.90 | HSP90AA1 (1.00) | HSP90AA1HSP90B1ERBB2HSP90AB1TRAP1 | |
| SCHEMBL20725179 | 0.89 | HSP90AA1 (0.81) | HSP90AA1HSP90B1CDC37 | |
| SCHEMBL12522859 | 0.89 | HSP90AA1 (0.80) | HSP90AA1HSP90B1ERBB2HSP90AB1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192687-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192687-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023006993-A1 | FUSED AMINO PYRIDINE OR PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CONGENITAL CENTRAL HYPOVENTILATION SYNDROME | ATMOSR (FR) | 2023-02-02 | — | — | WO | disclosed |
| US-11560377-B2 | Fused amino pyridine as HSP90 inhibitors | Guris, Inc. (US) | 2023-01-24 | — | — | US | disclosed |
| US-11560377-B2 | Fused amino pyridine as HSP90 inhibitors | Guris, Inc. (US) | 2023-01-24 | — | — | US | disclosed |
| US-20210308285-A1 | HSP90-TARGETED INFLAMMATION AND INFECTION IMAGING AND THERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-10-07 | — | — | US | disclosed |
| US-20210292317-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210292317-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-11065350-B2 | HSP90-targeted inflammation and infection imaging and therapy | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-07-20 | — | — | US | disclosed |
| US-20210138091-A1 | USES OF LABELED HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2021-05-13 | — | — | US | disclosed |
| US-8586605-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2069324-B1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2013-07-31 | — | — | EP | disclosed |
| US-8324240-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324240-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324240-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120237508-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. | 2012-09-20 | — | — | US | disclosed |
| US-20120237508-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. | 2012-09-20 | — | — | US | disclosed |
| US-20080234314-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. | 2008-09-25 | — | — | US | disclosed |
| US-20080234314-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. | 2008-09-25 | — | — | US | disclosed |
| US-20080234314-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120237508-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | HSP90AA1 4/4885HSP90B1 1/4885ERBB2 415/4885 |
| US-11065350-B2 | HSP90-targeted inflammation and infection imaging and therapy | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AA1 2/4885HSP90B1 3/4885ERBB2 79/4885 |
| US-20230192687-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | HSP90AA1 4/4885HSP90B1 1/4885ERBB2 415/4885 |
| US-20080234314-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | HSP90AA1 4/4885HSP90B1 1/4885ERBB2 415/4885 |
| US-20210292317-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | HSP90AA1 4/4885HSP90B1 1/4885ERBB2 415/4885 |
| US-11560377-B2 | Fused amino pyridine as HSP90 inhibitors | HSP90B1, HSP90AB1, HSP90AB2P | HSP90AA1 4/4885HSP90B1 1/4885ERBB2 415/4885 |
| US-20210138091-A1 | USES OF LABELED HSP90 INHIBITORS | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AA1 3/4885HSP90B1 2/4885ERBB2 711/4885 |
| US-20210308285-A1 | HSP90-TARGETED INFLAMMATION AND INFECTION IMAGING AND THERAPY | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AA1 2/4885HSP90B1 3/4885ERBB2 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.